Valuation: Evofem Biosciences, Inc.

Market Cap 1.11M 978K 909K 834K 1.57M 107M 1.59M 10.8M 4.22M 52.71M 4.18M 4.09M 182M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.53M 48.77M 45.36M 41.62M 78.2M 5.35B 79.41M 539M 210M 2.63B 208M 204M 9.09B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+7.59%
1 week+13.33%
Current month+6.25%
1 month+1.19%
3 months+1.19%
6 months-6.59%
Current year-10.53%
1 week 0.01
Extreme 0.007
0.01
1 month 0.01
Extreme 0.007
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.68
5 years 0
Extreme 0.0008
1,826.62
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
1/12/24 A Sell

Chief Financial Officer

104 0.0010%
12/21/23 A Sell

Director

10 0.0001%
4/13/23 A Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+7.59%+13.33%-9.57%-98.86% 1.11M
+0.86%+1.43%+48.50%+160.39% 1,057B
+1.59%+4.09%+55.34%+53.96% 624B
+0.95%+1.91%+35.91%+81.14% 454B
+1.60%+7.09%+35.90%+29.32% 341B
-0.60%+2.95%+36.28%+39.04% 297B
-0.14%+0.33%+18.70%+17.64% 262B
+0.09%-4.53%-27.60%-42.19% 215B
+1.22%+2.66%+21.87%+59.73% 201B
-1.18%-3.70%+14.23%+66.51% 162B
Average +1.09%+0.70%+22.96%+36.67% 361.4B
Weighted average by Cap. +0.58%+1.57%+36.19%+77.48%

Financials

2024 2025
Net sales 19.36M 17.01M 15.82M 14.51M 27.27M 1.86B 27.69M 188M 73.37M 917M 72.69M 71.12M 3.17B 20.18M 17.73M 16.49M 15.13M 28.42M 1.94B 28.86M 196M 76.48M 956M 75.77M 74.13M 3.3B
Net income -8.86M -7.78M -7.24M -6.64M -12.48M -853M -12.67M -85.94M -33.57M -419M -33.26M -32.54M -1.45B 391K 343K 319K 293K 551K 37.65M 559K 3.79M 1.48M 18.51M 1.47M 1.44M 64.01M
Net Debt 45.84M 40.26M 37.44M 34.36M 64.56M 4.41B 65.55M 445M 174M 2.17B 172M 168M 7.5B 54.42M 47.79M 44.45M 40.79M 76.63M 5.24B 77.82M 528M 206M 2.58B 204M 200M 8.91B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
23/07/26 $0.008400 +8.39% 89,764
22/07/26 $0.007750 -3.13% 123,319
21/07/26 $0.008000 -0.74% 167,779
20/07/26 $0.008060 +4.68% 26,537
17/07/26 $0.007700 +2.67% 12,087

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock